Judy E Stern1, Daksha Gopal2, Rebecca F Liberman3, Marlene Anderka3, Milton Kotelchuck4, Barbara Luke5. 1. Department of Obstetrics and Gynecology and Pathology, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire. Electronic address: judy.e.stern@dartmouth.edu. 2. Department of Community Health Sciences, Boston University, Boston, Massachusetts. 3. Center for Birth Defects Research and Prevention, Massachusetts Department of Public Health, Boston, Massachusetts. 4. Department of Pediatrics, Harvard Medical School Boston, Boston, Massachusetts. 5. Department of Obstetrics, Gynecology, and Reproductive Biology, Michigan State University, East Lansing, Michigan.
Abstract
OBJECTIVE: To assess the validity of outcome data reported to the Society for Assisted Reproductive Technology Clinic Outcome Reporting System (SART CORS) compared with data from vital records and the birth defects registry in Massachusetts. DESIGN: Longitudinal cohort. SETTING: Not applicable. PARTICIPANT(S): A total of 342,035 live births and fetal deaths from Massachusetts mothers giving birth in the state from July 1, 2004, to December 31, 2008; 9,092 births and fetal deaths were from mothers who had conceived with the use of assisted reproductive technology (ART) and whose cycle data had been reported to the SART CORS. INTERVENTION(S): Not applicable. MAIN OUTCOME MEASURE(S): Percentage agreement between maternal race and ethnicity, delivery outcome (live birth or fetal death), plurality (singleton, twin, or triplet+), delivery date, and singleton birth weight reported in the SART CORS versus vital records; sensitivity and specificity for birth defects among singletons as reported in the SART CORS versus the Massachusetts Birth Defects Monitoring Program (BDMP). RESULT(S): There was >95% agreement between the SART CORS and vital records for fields of maternal race/ethnicity, live birth/fetal death, and plurality; birth outcome date was within 1 day with 94.9% agreement and birth weight was within 100 g with 89.6% agreement. In contrast, sensitivity for report of any birth defect was 38.6%, with a range of 18.4%-50.0%, for specific birth defect categories. CONCLUSION(S): Although most SART CORS outcome fields are accurately reported, birth defect variables showed poor sensitivity compared with the gold standard data from the BDMP. We suggest that reporting of birth defects be discontinued.
OBJECTIVE: To assess the validity of outcome data reported to the Society for Assisted Reproductive Technology Clinic Outcome Reporting System (SART CORS) compared with data from vital records and the birth defects registry in Massachusetts. DESIGN: Longitudinal cohort. SETTING: Not applicable. PARTICIPANT(S): A total of 342,035 live births and fetal deaths from Massachusetts mothers giving birth in the state from July 1, 2004, to December 31, 2008; 9,092 births and fetal deaths were from mothers who had conceived with the use of assisted reproductive technology (ART) and whose cycle data had been reported to the SART CORS. INTERVENTION(S): Not applicable. MAIN OUTCOME MEASURE(S): Percentage agreement between maternal race and ethnicity, delivery outcome (live birth or fetal death), plurality (singleton, twin, or triplet+), delivery date, and singleton birth weight reported in the SART CORS versus vital records; sensitivity and specificity for birth defects among singletons as reported in the SART CORS versus the Massachusetts Birth Defects Monitoring Program (BDMP). RESULT(S): There was >95% agreement between the SART CORS and vital records for fields of maternal race/ethnicity, live birth/fetal death, and plurality; birth outcome date was within 1 day with 94.9% agreement and birth weight was within 100 g with 89.6% agreement. In contrast, sensitivity for report of any birth defect was 38.6%, with a range of 18.4%-50.0%, for specific birth defect categories. CONCLUSION(S): Although most SART CORS outcome fields are accurately reported, birth defect variables showed poor sensitivity compared with the gold standard data from the BDMP. We suggest that reporting of birth defects be discontinued.
Authors: Barbara Luke; Morton B Brown; Ethan Wantman; Avi Lederman; William Gibbons; Glenn L Schattman; Rogerio A Lobo; Richard E Leach; Judy E Stern Journal: N Engl J Med Date: 2012-06-28 Impact factor: 91.245
Authors: Laura A Schieve; Sonja A Rasmussen; Germaine M Buck; Diana E Schendel; Meredith A Reynolds; Victoria C Wright Journal: Obstet Gynecol Date: 2004-06 Impact factor: 7.661
Authors: Bengt Källén; Orvar Finnström; Anna Lindam; Emma Nilsson; Karl-Gösta Nygren; Petra Olausson Otterblad Journal: Birth Defects Res A Clin Mol Teratol Date: 2010-03
Authors: Jennifer F Knudtson; Courtney M Failor; Jonathan A Gelfond; Martin W Goros; Tiencheng Arthur Chang; Robert S Schenken; Randal D Robinson Journal: Fertil Steril Date: 2017-08-30 Impact factor: 7.329
Authors: Jessica E McLaughlin; Byeong Y Choi; Qianqian Liu; Jonathan A Gelfond; Randal D Robinson; T Arthur Chang; Jennifer F Knudtson Journal: J Assist Reprod Genet Date: 2019-11-12 Impact factor: 3.412
Authors: Barbara Luke; Morton B Brown; Ethan Wantman; Nina E Forestieri; Marilyn L Browne; Sarah C Fisher; Mahsa M Yazdy; Mary K Ethen; Mark A Canfield; Stephanie Watkins; Hazel B Nichols; Leslie V Farland; Sergio Oehninger; Kevin J Doody; Michael L Eisenberg; Valerie L Baker Journal: Hum Reprod Date: 2021-01-01 Impact factor: 6.918